Clinical Trial Update: Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT) [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial evaluating serplulimab plus weekly paclitaxel and carboplatin in triple-negative breast cancer; the study status is not yet recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)
• Serplulimab (serplulimab)

Snippet

Sponsor: RenJi Hospital | Conditions: Triple Negative Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING